After a right-wing protest, Prime Minister Netanyahu said Israel would not sign onto the pact, which is not legally binding and which Australia, Hungary and Austria also declined to join
Reported by Haaretz 2 hours ago.
Following U.S.: Israel will not join UN migrant rights initiative
↧
↧
Milton Tadeau Pimenta appointed Managing Director of CEVA Logistics' Australia & New Zealand cluster
EQS Group-News: CEVA Logistics AG / Key word(s): Change of Personnel
20.11.2018 / 17:37
--------------------
*Baar, Switzerland, 20 November, 2018 - CEVA Logistics has appointed Milton Tadeau Pimenta as Managing Director of its Australia & New Zealand cluster. Currently head of Contract Logistics in South America for the company, he will take up his position in January 2019, reporting directly to CEO, Xavier Urbain.*
He takes over from Carlos Velez Rodriguez who is leaving CEVA to pursue other career opportunities but who will work with Pimenta to ensure a smooth handover.
Pimenta joined CEVA 17 years ago and is a results driven, performance-focused team leader with a wealth of experience across both Freight Management and Contract Logistics. He has previously lived in both Australia and Asia and has extensive knowledge of the industry there.
Speaking about Pimenta's promotion to his new role Xavier Urbain says: "Milton is a very astute operator with an energetic, commercial mind. He is a true team motivator who is ideally placed to lead the Australia & New Zealand cluster in the next step of its development. I also want to thank Carlos for his valuable contribution in the turnaround of the business there and for developing one of the most impressive Contract Logistics campuses we have in the CEVA world".
*For additional information please contact: *
*Investors:*
Pierre Benaich
SVP Investor Relations
pierre.benaich@cevalogistics.com
+41 41 547 0048
*Media:*
Matthias Hochuli
Group Head of Marketing and Communications
matthias.hochuli@cevalogistics.com
+41 41 547 00 52
Cathy Howe
Pilot Marketing
ch@pilotmarketing.co.uk
Tel: +44 (0)208 941 5381
*CEVA - Making business flow*
CEVA Logistics, a global asset-light third-party logistics company, designs and operates industry leading supply-chain solutions for large and medium-size national and multinational companies. Its integrated network in Freight Management and Contract Logistics spans more than 160 countries. Approximately 56,000 employees are dedicated to delivering effective solutions across a variety of industry sectors where CEVA applies its operational expertise to provide best-in-class services. CEVA generated revenue of $7 billion and adjusted EBITDA of $280 million in 2017. CEVA Logistics is listed on SIX Swiss Exchange under ticker symbol CEVA. For more information, please visit www.cevalogistics.com.
--------------------
End of Corporate News -------------------- Reported by EQS Group 1 hour ago.
20.11.2018 / 17:37
--------------------
*Baar, Switzerland, 20 November, 2018 - CEVA Logistics has appointed Milton Tadeau Pimenta as Managing Director of its Australia & New Zealand cluster. Currently head of Contract Logistics in South America for the company, he will take up his position in January 2019, reporting directly to CEO, Xavier Urbain.*
He takes over from Carlos Velez Rodriguez who is leaving CEVA to pursue other career opportunities but who will work with Pimenta to ensure a smooth handover.
Pimenta joined CEVA 17 years ago and is a results driven, performance-focused team leader with a wealth of experience across both Freight Management and Contract Logistics. He has previously lived in both Australia and Asia and has extensive knowledge of the industry there.
Speaking about Pimenta's promotion to his new role Xavier Urbain says: "Milton is a very astute operator with an energetic, commercial mind. He is a true team motivator who is ideally placed to lead the Australia & New Zealand cluster in the next step of its development. I also want to thank Carlos for his valuable contribution in the turnaround of the business there and for developing one of the most impressive Contract Logistics campuses we have in the CEVA world".
*For additional information please contact: *
*Investors:*
Pierre Benaich
SVP Investor Relations
pierre.benaich@cevalogistics.com
+41 41 547 0048
*Media:*
Matthias Hochuli
Group Head of Marketing and Communications
matthias.hochuli@cevalogistics.com
+41 41 547 00 52
Cathy Howe
Pilot Marketing
ch@pilotmarketing.co.uk
Tel: +44 (0)208 941 5381
*CEVA - Making business flow*
CEVA Logistics, a global asset-light third-party logistics company, designs and operates industry leading supply-chain solutions for large and medium-size national and multinational companies. Its integrated network in Freight Management and Contract Logistics spans more than 160 countries. Approximately 56,000 employees are dedicated to delivering effective solutions across a variety of industry sectors where CEVA applies its operational expertise to provide best-in-class services. CEVA generated revenue of $7 billion and adjusted EBITDA of $280 million in 2017. CEVA Logistics is listed on SIX Swiss Exchange under ticker symbol CEVA. For more information, please visit www.cevalogistics.com.
--------------------
End of Corporate News -------------------- Reported by EQS Group 1 hour ago.
↧
Sport24.co.za | Injured Ashton ruled out of Wallaby clash
Wing Chris Ashton is unavailable for England's clash Australia because of a calf injury, forwards coach Steve Borthwick has confirmed.
Reported by News24 1 hour ago.
↧
999 call of gay pharmacist accused of strangling wife in bid to claim £2m life insurance
The prosecution say Mitesh Patel, 37, murdered his 34-year-old wife Jessica so he could start a new life in Australia with the man he really loved, and that he had been unfaithful to her.
Reported by MailOnline 43 minutes ago.
↧
Leicester Tigers coach Geordan Murphy welcomes England stance on Manu Tuilagi injury
Tuilagi is set to miss the game against Australia with a groin problem
Reported by Leicester Mercury 1 hour ago.
↧
↧
ARYZTA AG: Regulatory Release to Irish Stock Exchange - Total Voting Rights and Share Capital
ARYZTA AG: Regulatory Release to Irish Stock Exchange - Total Voting Rights and Share Capital
Schlieren / Switzerland, 20 November 2018
In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, ARYZTA AG advises that, following completion of the 10 for 1 rights issue and the issue of 900,184,940 new ARYZTA shares, the total number of registered shares of nominal value CHF0.02 each in issue as of the date of this notice is 993,105,727.
The Company holds 2,902,293 registered shares in treasury. Therefore, the total number of voting rights is 990,203,434
The above figure of 990,203,434 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the (Irish) Transparency (Directive 2004/109/EC) Regulations 2007 and the Transparency Rules.
This announcement is made by ARYZTA arising from the requirements of its secondary listing on the Irish Stock Exchange (ISE).
ARYZTA AG ('ARYZTA') is a global food business with a leadership position in speciality bakery. ARYZTA is based in Schlieren, Switzerland, with operations in North America, South America, Europe, Asia, Australia and New Zealand. ARYZTA has a primary listing on the SIX Swiss Exchange and a secondary listing on the ISE Irish Exchange (SIX: ARYN, ISE: YZA).
Enquiries:
Investor Relations
ARYZTA AG
Tel: +41 (0) 44 583 42 00
info@aryzta.com Reported by GlobeNewswire 1 hour ago.
Schlieren / Switzerland, 20 November 2018
In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, ARYZTA AG advises that, following completion of the 10 for 1 rights issue and the issue of 900,184,940 new ARYZTA shares, the total number of registered shares of nominal value CHF0.02 each in issue as of the date of this notice is 993,105,727.
The Company holds 2,902,293 registered shares in treasury. Therefore, the total number of voting rights is 990,203,434
The above figure of 990,203,434 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the (Irish) Transparency (Directive 2004/109/EC) Regulations 2007 and the Transparency Rules.
This announcement is made by ARYZTA arising from the requirements of its secondary listing on the Irish Stock Exchange (ISE).
ARYZTA AG ('ARYZTA') is a global food business with a leadership position in speciality bakery. ARYZTA is based in Schlieren, Switzerland, with operations in North America, South America, Europe, Asia, Australia and New Zealand. ARYZTA has a primary listing on the SIX Swiss Exchange and a secondary listing on the ISE Irish Exchange (SIX: ARYN, ISE: YZA).
Enquiries:
Investor Relations
ARYZTA AG
Tel: +41 (0) 44 583 42 00
info@aryzta.com Reported by GlobeNewswire 1 hour ago.
↧
Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone
· Vamorolone in clinical development for Duchenne muscular dystrophy (DMD) by ReveraGen BioPharma Inc. - pivotal VISION-DMD Phase 2b study ongoing
· Vamorolone has the potential to become standard of care in young patients with DMD
· Positions Santhera as a leading company in the DMD space with two late-stage assets addressing the medical need of DMD patients at all disease stages
· Idorsia to become the largest shareholder in Santhera with a 13.3% equity stake
*Pratteln and Allschwil, Switzerland, November 20, 2018*
Santhera Pharmaceuticals (SIX: SANN) and Idorsia Ltd (SIX: IDIA) have entered into an agreement under which Santhera will acquire the option to exclusively in-license, by way of sub-license, the first-in-class dissociative steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Initial clinical data suggest that vamorolone has the anti-inflammatory efficacy of steroids with reduced steroid-associated safety concerns, which would represent a significant improvement over current standard of care glucocorticoid therapy in patients with Duchenne muscular dystrophy (DMD), vamorolone's lead indication.
*Thomas Meier, PhD, Chief Executive Officer of Santhera, said:*
"Vamorolone is a highly promising drug candidate for the treatment of patients with DMD and a perfect strategic fit alongside idebenone. Our late-stage DMD drug portfolio covers a broad DMD patient spectrum, irrespective of genetic background, disease stage or age. This agreement underscores our strategy of in-licensing high-quality, late-stage rare disease assets, which leverage our existing capabilities and expertise. We are also delighted to welcome Idorsia as our largest shareholder and partner and look forward to working with ReveraGen in the development of vamorolone, which has the potential to replace standard glucocorticoids as treatment for DMD."
*Vamorolone - first-in-class dissociative steroid*
Vamorolone is a first-in-class drug candidate that binds to the same receptors as glucocorticoids but modifies the downstream activity of the receptors. This has the potential to 'dissociate' efficacy from typical steroid safety concerns and therefore could replace existing glucocorticoids, the current standard of care in children and adolescent patients with DMD. There is significant unmet medical need in this patient group as high dose glucocorticoids have severe systemic side effects, which limit long-term usage.
Vamorolone was discovered by US-based ReveraGen BioPharma Inc. and has been developed with participation in funding and design of studies by 12 international non-profit foundations, the US National Institutes of Health, the US Department of Defense and the European Commission's Horizon 2020 program. Actelion had acquired an option to license the product in 2016. This option was subsequently transferred to Idorsia following the acquisition of Actelion by Johnson & Johnson in 2017.
*Eric Hoffman, PhD, Chief Executive Officer of ReveraGen, commented:*
"Our hope for vamorolone is that it can replace existing glucocorticoids in DMD therapy. Early clinical development of vamorolone in patients with DMD, using an innovative approach with an array of pre-selected biomarkers in multiple contexts of use, suggests that vamorolone preserves anti-inflammatory efficacy while decreasing steroid-associated safety concerns. I am delighted to work with Santhera to advance this exciting therapeutic candidate for patients with DMD."
*Vamorolone in DMD*
Following single and multiple ascending dose clinical pharmacology studies (VBP15-001) in healthy volunteers [1] vamorolone completed a Phase 2a study (VBP15-002) in 48 boys with DMD aged 4 to
The ongoing Phase 2b VISION-DMD study (VBP15-004) builds on the available promising preliminary safety and efficacy data from Phase 2a and is designed to bridge exploratory biomarker data to clinical outcomes. This pivotal study will enroll approximately 120 boys aged 4 to
The study is being conducted at approximately 30 sites across North America, Europe, Israel and Australia. Enrolment, which began in August 2018, is expected to take about 12 months, with a total study duration of about 24 months. If successful, the data filing with health authorities in the US is anticipated by the end of 2020 and in the EU in 2021. Vamorolone has received Orphan Drug Designation in the US and in Europe and fast-track status in the US.
Santhera management anticipates peak sales potential for vamorolone for the DMD indication of USD 500 million.
*The Agreement*
Under the terms of the agreement, Idorsia will grant Santhera the option to obtain an exclusive sub-license for vamorolone in all indications and all territories except Japan and South Korea. Idorsia will receive as consideration for entering into the agreement 1,000,000 (one million) new registered shares from Santhera's existing authorized share capital and an upfront cash component of USD 20 million, of which USD 15 million is intended to compensate Idorsia for its investment into the Phase 2b VISION-DMD study currently conducted by ReveraGen. While the cash component of the consideration is subject to financing, the share component of the consideration is unconditional and, like the cash component, not redeemable under any circumstances. As a consequence of the transaction, Idorsia will become the largest shareholder in Santhera with a 13.3% equity position. The shares to be issued to Idorsia will be subject to a lock-up undertaking expiring if and when vamorolone receives marketing authorization in DMD in the United States. Santhera may exercise the option upon receipt of data from the Phase 2b VISION-DMD study (VBP15-004) and following a one-time consideration to Idorsia of USD 30 million.
Following the exercise of the worldwide vamorolone license option by Idorsia and exercise of the vamorolone sub-license option for all territories worldwide except Japan and South Korea by Santhera, Santhera will pay to Idorsia regulatory and commercial milestone payments of up to USD 80 million in the DMD indication and four one-time sales milestone payments of up to USD 130 million in aggregate. Regulatory milestone payments by Santhera to Idorsia for three additional indications amount to up to USD 205 million in aggregate. Upon commercialization of vamorolone, Santhera has committed to pay tiered royalties ranging from a single-digit percentage to low double-digit percentage on the annual net sales of vamorolone to Idorsia.
*Jean-Paul Clozel, MD, Chief Executive Officer of Idorsia, concluded: *
"With four compounds in late-stage clinical development and more innovative compounds coming through the pipeline, Idorsia's newly established commercial function has many assets to focus on. We have decided to hand the option to license vamorolone to Santhera because they are ideally placed to maximize the potential of this asset. If successful, Santhera's network and expertise in the field of DMD will allow patients to benefit from this potential new treatment approach as soon as possible. In addition, with this agreement we become Santhera's largest shareholder, so we remain highly motivated and committed to make vamorolone a success."
*Notes to the editor*
*About Santhera *
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. Santhera's Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. For further information, please visit www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
*About ReveraGen BioPharma*
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen's lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan's Quest, Alex's Wish, DuchenneUK, Pietro's Fight, Michael's Cause, and Duchenne Research Fund. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020). www.reveragen.com
*About Idorsia*
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 700 highly qualified specialists dedicated to realizing our ambitious targets.
*About the exclusive worldwide license agreement between Idorsia and ReveraGen*
Idorsia's agreement with ReveraGen relating to the vamorolone license option was last renewed and amended on November 5, 2018. Under the agreement, as amended, Idorsia is entitled to exercise an option to obtain the exclusive worldwide license rights relating to vamorolone at any time, but not later than upon receipt of the Phase 2b study results in exchange for a consideration of USD 20 million. If the option is exercised, ReveraGen will be entitled to regulatory and commercial milestone payments from Idorsia of up to USD 75 million in the DMD indication and three one-time sales milestone payments of up to USD 120 million in aggregate. Regulatory milestone payments by Idorsia to ReveraGen for three additional indications amount to up to USD 190 million in aggregate. Upon commercialization of vamorolone, Idorsia has committed to pay tiered single-digit to low double-digit royalties on the annual net sales of vamorolone to ReveraGen.
*References*
[1] Hoffman E et al. (2018). Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134: 43-52
[2] Conklin LS et al. (2018). Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research 136:140-150.
*For further information, please contact*
*Santhera*
Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, CH-4133 Pratteln
public-relations@santhera.com or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
For Investors:
investor-relations@santhera.com or
Christoph Rentsch, Chief Financial Officer Hans Vitzthum, LifeSci Advisors
Europe: +41 61 906 89 65 USA: +1 212 915 2568
christoph.rentsch@santhera.com hans@lifesciadvisors.com
*Santhera Webcast & Conference Call *
Santhera will hold an audio webcast / conference call tomorrow, November 21, 2018 at 13:00 CET, 12:00 GMT, 07:00 EST to discuss the agreement on vamorolone. Participants are invited to join either the audio webcast or telephone conference 10-15 minutes before the start:
Webcast: click this link to access the webcast
Telephone conference: dial one of the following numbers (no code required):
Europe: +41 58 310 50 00
UK: +44 207 107 0613
USA: +1 631 570 5613
*Idorsia*
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10
www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
*Attachment*
· Press Release PDF.pdf Reported by GlobeNewswire 1 hour ago.
· Vamorolone has the potential to become standard of care in young patients with DMD
· Positions Santhera as a leading company in the DMD space with two late-stage assets addressing the medical need of DMD patients at all disease stages
· Idorsia to become the largest shareholder in Santhera with a 13.3% equity stake
*Pratteln and Allschwil, Switzerland, November 20, 2018*
Santhera Pharmaceuticals (SIX: SANN) and Idorsia Ltd (SIX: IDIA) have entered into an agreement under which Santhera will acquire the option to exclusively in-license, by way of sub-license, the first-in-class dissociative steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Initial clinical data suggest that vamorolone has the anti-inflammatory efficacy of steroids with reduced steroid-associated safety concerns, which would represent a significant improvement over current standard of care glucocorticoid therapy in patients with Duchenne muscular dystrophy (DMD), vamorolone's lead indication.
*Thomas Meier, PhD, Chief Executive Officer of Santhera, said:*
"Vamorolone is a highly promising drug candidate for the treatment of patients with DMD and a perfect strategic fit alongside idebenone. Our late-stage DMD drug portfolio covers a broad DMD patient spectrum, irrespective of genetic background, disease stage or age. This agreement underscores our strategy of in-licensing high-quality, late-stage rare disease assets, which leverage our existing capabilities and expertise. We are also delighted to welcome Idorsia as our largest shareholder and partner and look forward to working with ReveraGen in the development of vamorolone, which has the potential to replace standard glucocorticoids as treatment for DMD."
*Vamorolone - first-in-class dissociative steroid*
Vamorolone is a first-in-class drug candidate that binds to the same receptors as glucocorticoids but modifies the downstream activity of the receptors. This has the potential to 'dissociate' efficacy from typical steroid safety concerns and therefore could replace existing glucocorticoids, the current standard of care in children and adolescent patients with DMD. There is significant unmet medical need in this patient group as high dose glucocorticoids have severe systemic side effects, which limit long-term usage.
Vamorolone was discovered by US-based ReveraGen BioPharma Inc. and has been developed with participation in funding and design of studies by 12 international non-profit foundations, the US National Institutes of Health, the US Department of Defense and the European Commission's Horizon 2020 program. Actelion had acquired an option to license the product in 2016. This option was subsequently transferred to Idorsia following the acquisition of Actelion by Johnson & Johnson in 2017.
*Eric Hoffman, PhD, Chief Executive Officer of ReveraGen, commented:*
"Our hope for vamorolone is that it can replace existing glucocorticoids in DMD therapy. Early clinical development of vamorolone in patients with DMD, using an innovative approach with an array of pre-selected biomarkers in multiple contexts of use, suggests that vamorolone preserves anti-inflammatory efficacy while decreasing steroid-associated safety concerns. I am delighted to work with Santhera to advance this exciting therapeutic candidate for patients with DMD."
*Vamorolone in DMD*
Following single and multiple ascending dose clinical pharmacology studies (VBP15-001) in healthy volunteers [1] vamorolone completed a Phase 2a study (VBP15-002) in 48 boys with DMD aged 4 to
The ongoing Phase 2b VISION-DMD study (VBP15-004) builds on the available promising preliminary safety and efficacy data from Phase 2a and is designed to bridge exploratory biomarker data to clinical outcomes. This pivotal study will enroll approximately 120 boys aged 4 to
The study is being conducted at approximately 30 sites across North America, Europe, Israel and Australia. Enrolment, which began in August 2018, is expected to take about 12 months, with a total study duration of about 24 months. If successful, the data filing with health authorities in the US is anticipated by the end of 2020 and in the EU in 2021. Vamorolone has received Orphan Drug Designation in the US and in Europe and fast-track status in the US.
Santhera management anticipates peak sales potential for vamorolone for the DMD indication of USD 500 million.
*The Agreement*
Under the terms of the agreement, Idorsia will grant Santhera the option to obtain an exclusive sub-license for vamorolone in all indications and all territories except Japan and South Korea. Idorsia will receive as consideration for entering into the agreement 1,000,000 (one million) new registered shares from Santhera's existing authorized share capital and an upfront cash component of USD 20 million, of which USD 15 million is intended to compensate Idorsia for its investment into the Phase 2b VISION-DMD study currently conducted by ReveraGen. While the cash component of the consideration is subject to financing, the share component of the consideration is unconditional and, like the cash component, not redeemable under any circumstances. As a consequence of the transaction, Idorsia will become the largest shareholder in Santhera with a 13.3% equity position. The shares to be issued to Idorsia will be subject to a lock-up undertaking expiring if and when vamorolone receives marketing authorization in DMD in the United States. Santhera may exercise the option upon receipt of data from the Phase 2b VISION-DMD study (VBP15-004) and following a one-time consideration to Idorsia of USD 30 million.
Following the exercise of the worldwide vamorolone license option by Idorsia and exercise of the vamorolone sub-license option for all territories worldwide except Japan and South Korea by Santhera, Santhera will pay to Idorsia regulatory and commercial milestone payments of up to USD 80 million in the DMD indication and four one-time sales milestone payments of up to USD 130 million in aggregate. Regulatory milestone payments by Santhera to Idorsia for three additional indications amount to up to USD 205 million in aggregate. Upon commercialization of vamorolone, Santhera has committed to pay tiered royalties ranging from a single-digit percentage to low double-digit percentage on the annual net sales of vamorolone to Idorsia.
*Jean-Paul Clozel, MD, Chief Executive Officer of Idorsia, concluded: *
"With four compounds in late-stage clinical development and more innovative compounds coming through the pipeline, Idorsia's newly established commercial function has many assets to focus on. We have decided to hand the option to license vamorolone to Santhera because they are ideally placed to maximize the potential of this asset. If successful, Santhera's network and expertise in the field of DMD will allow patients to benefit from this potential new treatment approach as soon as possible. In addition, with this agreement we become Santhera's largest shareholder, so we remain highly motivated and committed to make vamorolone a success."
*Notes to the editor*
*About Santhera *
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. Santhera's Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. For further information, please visit www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
*About ReveraGen BioPharma*
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen's lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan's Quest, Alex's Wish, DuchenneUK, Pietro's Fight, Michael's Cause, and Duchenne Research Fund. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020). www.reveragen.com
*About Idorsia*
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 700 highly qualified specialists dedicated to realizing our ambitious targets.
*About the exclusive worldwide license agreement between Idorsia and ReveraGen*
Idorsia's agreement with ReveraGen relating to the vamorolone license option was last renewed and amended on November 5, 2018. Under the agreement, as amended, Idorsia is entitled to exercise an option to obtain the exclusive worldwide license rights relating to vamorolone at any time, but not later than upon receipt of the Phase 2b study results in exchange for a consideration of USD 20 million. If the option is exercised, ReveraGen will be entitled to regulatory and commercial milestone payments from Idorsia of up to USD 75 million in the DMD indication and three one-time sales milestone payments of up to USD 120 million in aggregate. Regulatory milestone payments by Idorsia to ReveraGen for three additional indications amount to up to USD 190 million in aggregate. Upon commercialization of vamorolone, Idorsia has committed to pay tiered single-digit to low double-digit royalties on the annual net sales of vamorolone to ReveraGen.
*References*
[1] Hoffman E et al. (2018). Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134: 43-52
[2] Conklin LS et al. (2018). Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research 136:140-150.
*For further information, please contact*
*Santhera*
Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, CH-4133 Pratteln
public-relations@santhera.com or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
For Investors:
investor-relations@santhera.com or
Christoph Rentsch, Chief Financial Officer Hans Vitzthum, LifeSci Advisors
Europe: +41 61 906 89 65 USA: +1 212 915 2568
christoph.rentsch@santhera.com hans@lifesciadvisors.com
*Santhera Webcast & Conference Call *
Santhera will hold an audio webcast / conference call tomorrow, November 21, 2018 at 13:00 CET, 12:00 GMT, 07:00 EST to discuss the agreement on vamorolone. Participants are invited to join either the audio webcast or telephone conference 10-15 minutes before the start:
Webcast: click this link to access the webcast
Telephone conference: dial one of the following numbers (no code required):
Europe: +41 58 310 50 00
UK: +44 207 107 0613
USA: +1 631 570 5613
*Idorsia*
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10
www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
*Attachment*
· Press Release PDF.pdf Reported by GlobeNewswire 1 hour ago.
↧
Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolon
· Vamorolone in clinical development for Duchenne muscular dystrophy (DMD) by ReveraGen BioPharma Inc. - pivotal VISION-DMD Phase IIb study ongoing
· Vamorolone has the potential to become standard of care in young patients with DMD
· Positions Santhera as a leading company in the DMD space with two late-stage assets addressing the medical need of DMD patients at all disease stages
· Idorsia to become the largest shareholder in Santhera with a 13.3% equity stake
*Pratteln and Allschwil, Switzerland, November 20, 2018 - Santhera Pharmaceuticals (SIX: SANN) and Idorsia Ltd (SIX: IDIA) have entered into an agreement under which Santhera will acquire the option to exclusively in-license, by way of sub-license, the first-in-class dissociative steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Initial clinical data suggest that vamorolone has the anti-inflammatory efficacy of steroids with reduced steroid-associated safety concerns, which would represent a significant improvement over current standard of care glucocorticoid therapy in patients with Duchenne muscular dystrophy (DMD), vamorolone's lead indication.*
*Thomas Meier, PhD, Chief Executive Officer of Santhera**, said:* "Vamorolone is a highly promising drug candidate for the treatment of patients with DMD and a perfect strategic fit alongside idebenone. Our late-stage DMD drug portfolio covers a broad DMD patient spectrum, irrespective of genetic background, disease stage or age. This agreement underscores our strategy of in-licensing high-quality, late-stage rare disease assets, which leverage our existing capabilities and expertise. We are also delighted to welcome Idorsia as our largest shareholder and partner and look forward to working with ReveraGen in the development of vamorolone, which has the potential to replace standard glucocorticoids as treatment for DMD."
*Vamorolone - first-in-class dissociative steroid*
Vamorolone is a first-in-class drug candidate that binds to the same receptors as glucocorticoids but modifies the downstream activity of the receptors. This has the potential to 'dissociate' efficacy from typical steroid safety concerns and therefore could replace existing glucocorticoids, the current standard of care in children and adolescent patients with DMD. There is significant unmet medical need in this patient group as high dose glucocorticoids have severe systemic side effects, which limit long-term usage.
Vamorolone was discovered by US-based ReveraGen BioPharma Inc. and has been developed with participation in funding and design of studies by 12 international non-profit foundations, the US National Institutes of Health, the US Department of Defense and the European Commission's Horizon 2020 program. Actelion had acquired an option to license the product in 2016. This option was subsequently transferred to Idorsia following the acquisition of Actelion by Johnson & Johnson in 2017.
*Eric Hoffman, PhD, Chief Executive Officer of ReveraGen,* *commented:* "Our hope for vamorolone is that it can replace existing glucocorticoids in DMD therapy. Early clinical development of vamorolone in patients with DMD, using an innovative approach with an array of pre-selected biomarkers in multiple contexts of use, suggests that vamorolone preserves anti-inflammatory efficacy while decreasing steroid-associated safety concerns. I am delighted to work with Santhera to advance this exciting therapeutic candidate for patients with DMD."
*Vamorolone in DMD*
Following single and multiple ascending dose clinical pharmacology studies (VBP15-001) in healthy volunteers [1] vamorolone completed a Phase IIa study (VBP15-002) in 48 boys with DMD aged 4 to
The ongoing Phase IIb VISION-DMD study (VBP15-004) builds on the available promising preliminary safety and efficacy data from Phase IIa and is designed to bridge exploratory biomarker data to clinical outcomes. This pivotal study will enroll approximately 120 boys aged 4 to
The study is being conducted at approximately 30 sites across North America, Europe, Israel and Australia. Enrolment, which began in August 2018, is expected to take about 12 months, with a total study duration of about 24 months. If successful, the data filing with health authorities in the US is anticipated by the end of 2020 and in the EU in 2021. Vamorolone has received Orphan Drug Designation in the US and in Europe and fast-track status in the US.
Santhera management anticipates peak sales potential for vamorolone for the DMD indication of USD 500 million.
*The Agreement*
Under the terms of the agreement, Idorsia will grant Santhera the option to obtain an exclusive sub-license for vamorolone in all indications and all territories except Japan and South Korea. Idorsia will receive as consideration for entering into the agreement 1,000,000 (one million) new registered shares from Santhera's existing authorized share capital and an upfront cash component of USD 20 million, of which USD 15 million is intended to compensate Idorsia for its investment into the Phase IIb VISION-DMD study currently conducted by ReveraGen. While the cash component of the consideration is subject to financing, the share component of the consideration is unconditional and, like the cash component, not redeemable under any circumstances. As a consequence of the transaction, Idorsia will become the largest shareholder in Santhera with a 13.3% equity position. The shares to be issued to Idorsia will be subject to a lock-up undertaking expiring if and when vamorolone receives marketing authorization in DMD in the United States. Santhera may exercise the option upon receipt of data from the Phase IIb VISION-DMD study (VBP15-004) and following a one-time consideration to Idorsia of USD 30 million.
Following the exercise of the worldwide vamorolone license option by Idorsia and exercise of the vamorolone sub-license option for all territories worldwide except Japan and South Korea by Santhera, Santhera will pay to Idorsia regulatory and commercial milestone payments of up to USD 80 million in the DMD indication and four one-time sales milestone payments of up to USD 130 million in aggregate. Regulatory milestone payments by Santhera to Idorsia for three additional indications amount to up to USD 205 million in aggregate. Upon commercialization of vamorolone, Santhera has committed to pay tiered royalties ranging from a single-digit percentage to low double-digit percentage on the annual net sales of vamorolone to Idorsia.
*Jean-Paul Clozel, MD, Chief Executive Officer of Idorsia, concluded: *"With four compounds in late-stage clinical development and more innovative compounds coming through the pipeline, Idorsia's newly established commercial function has many assets to focus on. We have decided to hand the option to license vamorolone to Santhera because they are ideally placed to maximize the potential of this asset. If successful, Santhera's network and expertise in the field of DMD will allow patients to benefit from this potential new treatment approach as soon as possible. In addition, with this agreement we become Santhera's largest shareholder, so we remain highly motivated and committed to make vamorolone a success."
Centerview Partners acted as exclusive strategic and financial advisor to Santhera for this transaction.
*Santhera Webcast & Conference Call *
Santhera will hold an audio webcast / conference call tomorrow, November 21, 2018 at 13:00 CET, 12:00 GMT, 07:00 EST to discuss the agreement on vamorolone. Participants are invited to join either the audio webcast or telephone conference 10-15 minutes before the start:
Webcast: click this link to access the webcast
Telephone conference: dial one of the following numbers (no code required):
Europe: +41 58 310 50 00
UK: +44 207 107 0613
USA: +1 631 570 5613
# # #
*Notes to the editor*
*About Santhera *
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. Santhera's Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. For further information, please visit www.santhera.com.
Raxone^® is a trademark of Santhera Pharmaceuticals.
*About ReveraGen BioPharma*
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen's lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan's Quest, Alex's Wish, DuchenneUK, Pietro's Fight, Michael's Cause, and Duchenne Research Fund. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020). www.reveragen.com
*About Idorsia*
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 700 highly qualified professionals dedicated to realizing our ambitious targets.
*About the exclusive worldwide license agreement between Idorsia and ReveraGen*
Idorsia's agreement with ReveraGen relating to the vamorolone license option was last renewed and amended on November 5, 2018. Under the agreement, as amended, Idorsia is entitled to exercise an option to obtain the exclusive worldwide license rights relating to vamorolone at any time, but not later than upon receipt of the Phase IIb study results in exchange for a consideration of USD 20 million. If the option is exercised, ReveraGen will be entitled to regulatory and commercial milestone payments from Idorsia of up to USD 75 million in the DMD indication and three one-time sales milestone payments of up to USD 120 million in aggregate. Regulatory milestone payments by Idorsia to ReveraGen for three additional indications amount to up to USD 190 million in aggregate. Upon commercialization of vamorolone, Idorsia has committed to pay tiered single-digit to low double-digit royalties on the annual net sales of vamorolone to ReveraGen.
References
[1] Hoffman E et al. (2018). Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134: 43-52
[2] Conklin LS et al. (2018). Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research 136:140-150.
*For further information please contact: *
*Santhera*
Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, CH-4133 Pratteln
public-relations@santhera.com or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
For Investors:
investor-relations@santhera.com or
Christoph Rentsch, Chief Financial Officer Hans Vitzthum, LifeSci Advisors
Europe: +41 61 906 89 65 USA: +1 212 915 2568
christoph.rentsch@santhera.com hans@lifesciadvisors.com
*Idorsia*
Andrew C. Weiss,
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
Phone: +41 (0) 58 844 10 10
www.idorsia.com
*Disclaimer / Forward-looking statements *
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
*Attachment*
· News release agreement Santhera Idorsia.pdf Reported by GlobeNewswire 1 hour ago.
· Vamorolone has the potential to become standard of care in young patients with DMD
· Positions Santhera as a leading company in the DMD space with two late-stage assets addressing the medical need of DMD patients at all disease stages
· Idorsia to become the largest shareholder in Santhera with a 13.3% equity stake
*Pratteln and Allschwil, Switzerland, November 20, 2018 - Santhera Pharmaceuticals (SIX: SANN) and Idorsia Ltd (SIX: IDIA) have entered into an agreement under which Santhera will acquire the option to exclusively in-license, by way of sub-license, the first-in-class dissociative steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Initial clinical data suggest that vamorolone has the anti-inflammatory efficacy of steroids with reduced steroid-associated safety concerns, which would represent a significant improvement over current standard of care glucocorticoid therapy in patients with Duchenne muscular dystrophy (DMD), vamorolone's lead indication.*
*Thomas Meier, PhD, Chief Executive Officer of Santhera**, said:* "Vamorolone is a highly promising drug candidate for the treatment of patients with DMD and a perfect strategic fit alongside idebenone. Our late-stage DMD drug portfolio covers a broad DMD patient spectrum, irrespective of genetic background, disease stage or age. This agreement underscores our strategy of in-licensing high-quality, late-stage rare disease assets, which leverage our existing capabilities and expertise. We are also delighted to welcome Idorsia as our largest shareholder and partner and look forward to working with ReveraGen in the development of vamorolone, which has the potential to replace standard glucocorticoids as treatment for DMD."
*Vamorolone - first-in-class dissociative steroid*
Vamorolone is a first-in-class drug candidate that binds to the same receptors as glucocorticoids but modifies the downstream activity of the receptors. This has the potential to 'dissociate' efficacy from typical steroid safety concerns and therefore could replace existing glucocorticoids, the current standard of care in children and adolescent patients with DMD. There is significant unmet medical need in this patient group as high dose glucocorticoids have severe systemic side effects, which limit long-term usage.
Vamorolone was discovered by US-based ReveraGen BioPharma Inc. and has been developed with participation in funding and design of studies by 12 international non-profit foundations, the US National Institutes of Health, the US Department of Defense and the European Commission's Horizon 2020 program. Actelion had acquired an option to license the product in 2016. This option was subsequently transferred to Idorsia following the acquisition of Actelion by Johnson & Johnson in 2017.
*Eric Hoffman, PhD, Chief Executive Officer of ReveraGen,* *commented:* "Our hope for vamorolone is that it can replace existing glucocorticoids in DMD therapy. Early clinical development of vamorolone in patients with DMD, using an innovative approach with an array of pre-selected biomarkers in multiple contexts of use, suggests that vamorolone preserves anti-inflammatory efficacy while decreasing steroid-associated safety concerns. I am delighted to work with Santhera to advance this exciting therapeutic candidate for patients with DMD."
*Vamorolone in DMD*
Following single and multiple ascending dose clinical pharmacology studies (VBP15-001) in healthy volunteers [1] vamorolone completed a Phase IIa study (VBP15-002) in 48 boys with DMD aged 4 to
The ongoing Phase IIb VISION-DMD study (VBP15-004) builds on the available promising preliminary safety and efficacy data from Phase IIa and is designed to bridge exploratory biomarker data to clinical outcomes. This pivotal study will enroll approximately 120 boys aged 4 to
The study is being conducted at approximately 30 sites across North America, Europe, Israel and Australia. Enrolment, which began in August 2018, is expected to take about 12 months, with a total study duration of about 24 months. If successful, the data filing with health authorities in the US is anticipated by the end of 2020 and in the EU in 2021. Vamorolone has received Orphan Drug Designation in the US and in Europe and fast-track status in the US.
Santhera management anticipates peak sales potential for vamorolone for the DMD indication of USD 500 million.
*The Agreement*
Under the terms of the agreement, Idorsia will grant Santhera the option to obtain an exclusive sub-license for vamorolone in all indications and all territories except Japan and South Korea. Idorsia will receive as consideration for entering into the agreement 1,000,000 (one million) new registered shares from Santhera's existing authorized share capital and an upfront cash component of USD 20 million, of which USD 15 million is intended to compensate Idorsia for its investment into the Phase IIb VISION-DMD study currently conducted by ReveraGen. While the cash component of the consideration is subject to financing, the share component of the consideration is unconditional and, like the cash component, not redeemable under any circumstances. As a consequence of the transaction, Idorsia will become the largest shareholder in Santhera with a 13.3% equity position. The shares to be issued to Idorsia will be subject to a lock-up undertaking expiring if and when vamorolone receives marketing authorization in DMD in the United States. Santhera may exercise the option upon receipt of data from the Phase IIb VISION-DMD study (VBP15-004) and following a one-time consideration to Idorsia of USD 30 million.
Following the exercise of the worldwide vamorolone license option by Idorsia and exercise of the vamorolone sub-license option for all territories worldwide except Japan and South Korea by Santhera, Santhera will pay to Idorsia regulatory and commercial milestone payments of up to USD 80 million in the DMD indication and four one-time sales milestone payments of up to USD 130 million in aggregate. Regulatory milestone payments by Santhera to Idorsia for three additional indications amount to up to USD 205 million in aggregate. Upon commercialization of vamorolone, Santhera has committed to pay tiered royalties ranging from a single-digit percentage to low double-digit percentage on the annual net sales of vamorolone to Idorsia.
*Jean-Paul Clozel, MD, Chief Executive Officer of Idorsia, concluded: *"With four compounds in late-stage clinical development and more innovative compounds coming through the pipeline, Idorsia's newly established commercial function has many assets to focus on. We have decided to hand the option to license vamorolone to Santhera because they are ideally placed to maximize the potential of this asset. If successful, Santhera's network and expertise in the field of DMD will allow patients to benefit from this potential new treatment approach as soon as possible. In addition, with this agreement we become Santhera's largest shareholder, so we remain highly motivated and committed to make vamorolone a success."
Centerview Partners acted as exclusive strategic and financial advisor to Santhera for this transaction.
*Santhera Webcast & Conference Call *
Santhera will hold an audio webcast / conference call tomorrow, November 21, 2018 at 13:00 CET, 12:00 GMT, 07:00 EST to discuss the agreement on vamorolone. Participants are invited to join either the audio webcast or telephone conference 10-15 minutes before the start:
Webcast: click this link to access the webcast
Telephone conference: dial one of the following numbers (no code required):
Europe: +41 58 310 50 00
UK: +44 207 107 0613
USA: +1 631 570 5613
# # #
*Notes to the editor*
*About Santhera *
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. Santhera's Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. For further information, please visit www.santhera.com.
Raxone^® is a trademark of Santhera Pharmaceuticals.
*About ReveraGen BioPharma*
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen's lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan's Quest, Alex's Wish, DuchenneUK, Pietro's Fight, Michael's Cause, and Duchenne Research Fund. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020). www.reveragen.com
*About Idorsia*
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 700 highly qualified professionals dedicated to realizing our ambitious targets.
*About the exclusive worldwide license agreement between Idorsia and ReveraGen*
Idorsia's agreement with ReveraGen relating to the vamorolone license option was last renewed and amended on November 5, 2018. Under the agreement, as amended, Idorsia is entitled to exercise an option to obtain the exclusive worldwide license rights relating to vamorolone at any time, but not later than upon receipt of the Phase IIb study results in exchange for a consideration of USD 20 million. If the option is exercised, ReveraGen will be entitled to regulatory and commercial milestone payments from Idorsia of up to USD 75 million in the DMD indication and three one-time sales milestone payments of up to USD 120 million in aggregate. Regulatory milestone payments by Idorsia to ReveraGen for three additional indications amount to up to USD 190 million in aggregate. Upon commercialization of vamorolone, Idorsia has committed to pay tiered single-digit to low double-digit royalties on the annual net sales of vamorolone to ReveraGen.
References
[1] Hoffman E et al. (2018). Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134: 43-52
[2] Conklin LS et al. (2018). Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research 136:140-150.
*For further information please contact: *
*Santhera*
Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, CH-4133 Pratteln
public-relations@santhera.com or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
For Investors:
investor-relations@santhera.com or
Christoph Rentsch, Chief Financial Officer Hans Vitzthum, LifeSci Advisors
Europe: +41 61 906 89 65 USA: +1 212 915 2568
christoph.rentsch@santhera.com hans@lifesciadvisors.com
*Idorsia*
Andrew C. Weiss,
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
Phone: +41 (0) 58 844 10 10
www.idorsia.com
*Disclaimer / Forward-looking statements *
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
*Attachment*
· News release agreement Santhera Idorsia.pdf Reported by GlobeNewswire 1 hour ago.
↧
AUD/USD stays below 0.7250 as US Dollar Index continues to push higher
· *US Dollar Index recovers Monday's losses.*
· *Negative market sentiment weighs on Aussie.*
· *Coming up: Westpac Leading Index.*
Following a sharp drop in the European morning, the AUD/USD pair steadies around mid-0.72s before coming under a renewed selling pressure in the NA session. The pair, which slumped to a fresh five day low at 0.7232, was last seen trading at 0.7240, losing 0.75% on a daily basis.
Earlier today, People's Bank of China's Research Head Xu Zhong said that their latest policy change weighed on the economy. On a similar note, Chinese Finance Ministry official Tan Long stated that the downward pressure on the economy had strengthened on increasing uncertainties. Concerns over the economic slowdown in China caused the AUD to weaken amid Australia's strong trade ties with China.
Later in the day, the pair extended its decline as the greenback continued to outperform its rivals. With major European currencies struggling to make a decisive recovery vs the buck, the US Dollar Index rose to its highest level of the day at 96.67 to reflect the broad market interest. At the moment, the index is up 0.5% on the day at 96.65.
Today's data from the U.S. showed that housing starts increased 1.5% in October after falling 5.5% in September and building permits declined 0.6% to match the previous reading. In the early Asian session on Tuesday, the Melbourne Institute will release the Westpac Leading Index.
*Technical levels to consider*
The pair could face the first support at 0.7220 (100-DMA/20-DMA) ahead of 0.7185 (Nov. 14 low) 0.7160 (Nov. 13 low). On the upside, resistances align at 0.7300 (psychological level/daily high), 0.7340 (Nov. 16 high) and 0.7380 (Aug. 21 high). Reported by FXstreet.com 37 minutes ago.
· *Negative market sentiment weighs on Aussie.*
· *Coming up: Westpac Leading Index.*
Following a sharp drop in the European morning, the AUD/USD pair steadies around mid-0.72s before coming under a renewed selling pressure in the NA session. The pair, which slumped to a fresh five day low at 0.7232, was last seen trading at 0.7240, losing 0.75% on a daily basis.
Earlier today, People's Bank of China's Research Head Xu Zhong said that their latest policy change weighed on the economy. On a similar note, Chinese Finance Ministry official Tan Long stated that the downward pressure on the economy had strengthened on increasing uncertainties. Concerns over the economic slowdown in China caused the AUD to weaken amid Australia's strong trade ties with China.
Later in the day, the pair extended its decline as the greenback continued to outperform its rivals. With major European currencies struggling to make a decisive recovery vs the buck, the US Dollar Index rose to its highest level of the day at 96.67 to reflect the broad market interest. At the moment, the index is up 0.5% on the day at 96.65.
Today's data from the U.S. showed that housing starts increased 1.5% in October after falling 5.5% in September and building permits declined 0.6% to match the previous reading. In the early Asian session on Tuesday, the Melbourne Institute will release the Westpac Leading Index.
*Technical levels to consider*
The pair could face the first support at 0.7220 (100-DMA/20-DMA) ahead of 0.7185 (Nov. 14 low) 0.7160 (Nov. 13 low). On the upside, resistances align at 0.7300 (psychological level/daily high), 0.7340 (Nov. 16 high) and 0.7380 (Aug. 21 high). Reported by FXstreet.com 37 minutes ago.
↧
↧
Fleur East I'm A Celeb: Who is she and is Fleur vegan? How old is she and did she win The X Factor? All you need to know
Fleur East I'm A Celeb: Is Fleur vegan? [ITV] The X Factor star Fleur East, age 31, was the first contestant on the I'm A Celebrity 2018 line-up to be confirmed. Fleur sparked confusion just days into the series after eating meat, while it was reported that she was vegan. But who is the singer, and what happened to Fleur after The X Factor? Here's all you need to know... I'm A Celebrity 2018 line-up: Fleur East has landed in Australia [Tim Merry] Fleur East vegan: Does the star ...
Reported by OK! 17 minutes ago.
↧
News24.com | 3 men charged with planning mass killing in Australian city
Three men inspired by the Islamic State group were charged with planning a mass-casualty attack in Australia's second-largest city.
Reported by News24 29 minutes ago.
↧
Morrison to shun UN compact on migration
Australia will not be signing up to a UN-sponsored document on safe and orderly migration on the grounds it threatens the country's borders, News Corp reports.
Reported by SBS 3 minutes ago.
↧
Savaria Declares its Monthly Dividend
LAVAL, Québec, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, declared on November 21st a dividend of 3.5 cents ($0.035) per common share, in accordance with its monthly dividend policy, payable on December 14, 2018 to shareholders of record of the Corporation at the close of business on November 30, 2018. This is an eligible dividend within the meaning of the Income Tax Act.*About Savaria Corporation*
Savaria Corporation (savaria.com) is one of the global leaders in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts, elevators for home and commercial use, as well as ceiling lifts. It also manufactures and markets a comprehensive selection of pressure management products for the medical market, medical beds for the long-term care market, mattress overlays and foam pillows for the retail market and certain products for the industrial market. In addition, Savaria converts and adapts vehicles to be wheelchair accessible. Savaria records approximately 75% of its revenue outside of Canada, primarily in the United States. It operates a sales network of some 500 dealers worldwide and 28 direct sales offices in North America, Europe (Switzerland, Germany, Italy, Czech Republic and Poland), Australia and China. Savaria employs approximately 1,400 people globally and its plants are located in Canada: Laval and Magog (Québec), Brampton, Beamsville and Toronto (Ontario) and Surrey (British Columbia), in the United States at Greenville (South Carolina), in Huizhou (China) and in Milan (Italy).
*For further information*: * *
Marcel Bourassa
Chairman, President and
Chief Executive Officer
1-800-661-5112
marcel.bourassa@savaria.com
Hélène Bernier, CPA, CA
Vice President, Finance
1-800-931-5655, ext. 248
helene.bernier@savaria.com
* *
www.savaria.com
Facebook: https://www.facebook.com/savariabettermobility
Twitter: https://twitter.com/Mobilityforlife
* * Reported by GlobeNewswire 3 hours ago.
Savaria Corporation (savaria.com) is one of the global leaders in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts, elevators for home and commercial use, as well as ceiling lifts. It also manufactures and markets a comprehensive selection of pressure management products for the medical market, medical beds for the long-term care market, mattress overlays and foam pillows for the retail market and certain products for the industrial market. In addition, Savaria converts and adapts vehicles to be wheelchair accessible. Savaria records approximately 75% of its revenue outside of Canada, primarily in the United States. It operates a sales network of some 500 dealers worldwide and 28 direct sales offices in North America, Europe (Switzerland, Germany, Italy, Czech Republic and Poland), Australia and China. Savaria employs approximately 1,400 people globally and its plants are located in Canada: Laval and Magog (Québec), Brampton, Beamsville and Toronto (Ontario) and Surrey (British Columbia), in the United States at Greenville (South Carolina), in Huizhou (China) and in Milan (Italy).
*For further information*: * *
Marcel Bourassa
Chairman, President and
Chief Executive Officer
1-800-661-5112
marcel.bourassa@savaria.com
Hélène Bernier, CPA, CA
Vice President, Finance
1-800-931-5655, ext. 248
helene.bernier@savaria.com
* *
www.savaria.com
Facebook: https://www.facebook.com/savariabettermobility
Twitter: https://twitter.com/Mobilityforlife
* * Reported by GlobeNewswire 3 hours ago.
↧
↧
India vs Australia 1st T20I: Missed chances in field cost us dearly, says Dhawan after Brisbane loss
Opener Shikhar Dhawan Wednesday said poor fielding cost India the game after the visitors lost by four runs via D/L method against Australia in the tour opening first Twenty20 International here at the Gabba.
Reported by DNA 3 hours ago.
↧
Global Grain Conference Chooses Eka for Innovation Award
Eka earns top honors in the innovative finance category for its disruptive app-based platform that enables agri-businesses to better manage position and mitigate risks.
NORWALK, Conn. (PRWEB) November 21, 2018
Eka Software Solutions, the leading global provider of digital commodity management systems, was named 2018’s best provider in the “Innovative finance” category at the biggest agriculture trade show - Global Grains, Geneva.
Eka won the award for its revolutionary Digital Commodity Management (CM) Platform that is disrupting the agriculture industry by digitizing the value chain with powerful “out of the box” apps. Driven by machine learning algorithms, these apps allow agri-businesses to manage their risk better with round the clock breach alerts and in-built chat that help traders collaborate better and maximize profits.
Eka is witnessing revolutionary growth on its Digital CM Platform with over 20 commodity businesses switching to app-based workflows. These new customers span all geographies and industries, including industry disruptors like Farmer Business Network and Indigo, co-ops like Foremost Farms and Tereos, trading operations, and government bodies like Coffee Board of India.
Eka’s powerful apps help these businesses manage trade and risk, govern quality, trace food origin and provide better services to farmers, thus empowering them to grow more with less. The app-based platform goes live in just weeks, fueling rapid business growth.
Hosted during the biggest event in the industry calendar, the Global Grain Awards recognize excellence in the global grains and oilseeds community. Entries for the award are assessed by an independent judging committee and ranked against strict award criteria.
The judges chose Eka for:· Demonstrating strong volume of activity in the grains and oilseeds market with evidence of strong customer service
· Enabling commodity businesses to uncover new ways of managing profitability across the value chain, while retaining the ability to evolve with market dynamics and their influences
· Building an intelligent TRM platform enabling traders to better understand their position and mitigate risks
· Building a future-ready software solution
Commenting on the award, Manav Garg, CEO & Founder, Eka Software Solutions said, “We are honored to receive the 2018 Innovative Finance Award at Global Grain. It is a testament to our vision to disrupt the commodity industry, enabling it to get future ready, and a demonstration of the commitment and dedication of Eka’s team and their relentless pursuit of excellence.”
Learn more about the award at http://interactive.globalgrainevents.com/globalgrainawards.
About Eka’s Digital Commodity Management Platform
Eka’s modern commodity platform is designed for commodity companies that need to flex, grow, and adapt to market forces. It is the only digital commodity management platform that breaks monolithic E/CTRM systems into bite-sized chunks of powerful apps that work across the commodity value chain, thereby enabling faster, data-powered decisions.
About Eka:
Eka is the global leader in providing Commodity Management solutions driven by Cloud, Blockchain, Machine Learning and Analytics. Eka’s modern Commodity Management platform enables companies to efficiently and profitably meet the challenges of complex and volatile markets.
The company’s best-of-breed solutions manage commodity trading, enterprise risk, compliance, procurement, supply chain, operations, logistics, bulk handling, processing, and decision support. Eka partners with customers to accelerate growth, increase profitability, improve operational control, and manage risks and exposures. Eka is a team of 350 staff with offices in the Americas, Asia, Australia, and EMEA, serving a rapidly growing global client base across multiple commodity segments.
Learn more at http://www.ekaplus.com. Reported by PRWeb 3 hours ago.
NORWALK, Conn. (PRWEB) November 21, 2018
Eka Software Solutions, the leading global provider of digital commodity management systems, was named 2018’s best provider in the “Innovative finance” category at the biggest agriculture trade show - Global Grains, Geneva.
Eka won the award for its revolutionary Digital Commodity Management (CM) Platform that is disrupting the agriculture industry by digitizing the value chain with powerful “out of the box” apps. Driven by machine learning algorithms, these apps allow agri-businesses to manage their risk better with round the clock breach alerts and in-built chat that help traders collaborate better and maximize profits.
Eka is witnessing revolutionary growth on its Digital CM Platform with over 20 commodity businesses switching to app-based workflows. These new customers span all geographies and industries, including industry disruptors like Farmer Business Network and Indigo, co-ops like Foremost Farms and Tereos, trading operations, and government bodies like Coffee Board of India.
Eka’s powerful apps help these businesses manage trade and risk, govern quality, trace food origin and provide better services to farmers, thus empowering them to grow more with less. The app-based platform goes live in just weeks, fueling rapid business growth.
Hosted during the biggest event in the industry calendar, the Global Grain Awards recognize excellence in the global grains and oilseeds community. Entries for the award are assessed by an independent judging committee and ranked against strict award criteria.
The judges chose Eka for:· Demonstrating strong volume of activity in the grains and oilseeds market with evidence of strong customer service
· Enabling commodity businesses to uncover new ways of managing profitability across the value chain, while retaining the ability to evolve with market dynamics and their influences
· Building an intelligent TRM platform enabling traders to better understand their position and mitigate risks
· Building a future-ready software solution
Commenting on the award, Manav Garg, CEO & Founder, Eka Software Solutions said, “We are honored to receive the 2018 Innovative Finance Award at Global Grain. It is a testament to our vision to disrupt the commodity industry, enabling it to get future ready, and a demonstration of the commitment and dedication of Eka’s team and their relentless pursuit of excellence.”
Learn more about the award at http://interactive.globalgrainevents.com/globalgrainawards.
About Eka’s Digital Commodity Management Platform
Eka’s modern commodity platform is designed for commodity companies that need to flex, grow, and adapt to market forces. It is the only digital commodity management platform that breaks monolithic E/CTRM systems into bite-sized chunks of powerful apps that work across the commodity value chain, thereby enabling faster, data-powered decisions.
About Eka:
Eka is the global leader in providing Commodity Management solutions driven by Cloud, Blockchain, Machine Learning and Analytics. Eka’s modern Commodity Management platform enables companies to efficiently and profitably meet the challenges of complex and volatile markets.
The company’s best-of-breed solutions manage commodity trading, enterprise risk, compliance, procurement, supply chain, operations, logistics, bulk handling, processing, and decision support. Eka partners with customers to accelerate growth, increase profitability, improve operational control, and manage risks and exposures. Eka is a team of 350 staff with offices in the Americas, Asia, Australia, and EMEA, serving a rapidly growing global client base across multiple commodity segments.
Learn more at http://www.ekaplus.com. Reported by PRWeb 3 hours ago.
↧
Global ESD Bags Market to Surpass US$ 601.48 Million by 2026 – Coherent Market Insights
Seattle, Nov. 21, 2018 (GLOBE NEWSWIRE) -- The global ESD bags market was valued at US$ 339.90 million in 2017 and is projected to exhibit a CAGR of 6.9 % over the forecast period (2018 – 2026), owing to increasing demand for ESD bags from end-use industries across the globe. ESD bags such as anti-static bags are used to prevent electrostatic or static electricity from damaging electronic items during transportation.
*To know the latest trends and insights prevalent in this market, click the link below:*
*https://www.coherentmarketinsights.com/market-insight/esd-bags-market-2268*
*Key Trends and Analysis in the ESD Bags Market:*
Increasing demand for electronic products such as smartphones and tablets is expected to be a major factor driving growth of the global ESD bags market over the forecast period. ESD bags are used to prevent build-up of static charge in electronic products. These bags are generally used for shipping of electronic components and devices. For instance, according to the Australian Communications and Media Authority, in May 2012, number of smartphone owners in Australia was 8.67 million, which was an increase by 104% from 2011.
However, growing environmental concerns regarding plastic pollution is a major factor hindering growth of the global ESD bags market. According to a study published in the journal Science Advances, in June 2017, around 8.3 billion metric tons of plastic was manufactured, of which 6.3 billion metric tons was converted into plastic waste and only 9% was recycled worldwide.
*Request Sample Pages of this Report*
*Key Market Takeaways:*
· Among product type, anti-static bag segment held a significant market share in the global ESD bags market in 2017, owing to increasing demand for its applications in electronics industry. Major application of anti-static bag is packaging of electronic products. Computer components and items of a similar nature can be easily damaged by static discharge. Anti-static bags are used to maintain a static-free environment for electronic products.
· Asia Pacific accounted for a significant market share in 2017 in the global ESD bags market over the forecast period. This is owing to increasing demand for ESD bags such as anti-static bags from pharmaceutical industry in the region. ESD bags ensure that there is no electrostatic charge present inside the bag used for packaging of bulk drugs manufactured by the pharmaceutical industries. Furthermore, these bags are lightweight and have high load bearing capacity. According to India Brand Equity Foundation (IBEF), the pharmaceutical sector in India accounted for 2.4% of the global pharmaceutical industry in terms of value in 2017 and is expected to expand at a CAGR of 12.89% during 2015 to 2020
· Key players operating in the global ESD bags market include, 3M Company, Miller Packaging, Protective Packaging Corporation, Digi-Key Electronics, Daklapack Group, Dou Yee Enterprises (S) Pte Ltd., Advantek, Inc., Teknis Limited, Edco Supply Corporation, Naps Polybag Co, Katzke Paper Co, Statclean Technology (S) Pte Ltd, Elcom Ltd. and Electrotek Static Controls Pvt., Ltd.
CONTACT: Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com Reported by GlobeNewswire 3 hours ago.
*To know the latest trends and insights prevalent in this market, click the link below:*
*https://www.coherentmarketinsights.com/market-insight/esd-bags-market-2268*
*Key Trends and Analysis in the ESD Bags Market:*
Increasing demand for electronic products such as smartphones and tablets is expected to be a major factor driving growth of the global ESD bags market over the forecast period. ESD bags are used to prevent build-up of static charge in electronic products. These bags are generally used for shipping of electronic components and devices. For instance, according to the Australian Communications and Media Authority, in May 2012, number of smartphone owners in Australia was 8.67 million, which was an increase by 104% from 2011.
However, growing environmental concerns regarding plastic pollution is a major factor hindering growth of the global ESD bags market. According to a study published in the journal Science Advances, in June 2017, around 8.3 billion metric tons of plastic was manufactured, of which 6.3 billion metric tons was converted into plastic waste and only 9% was recycled worldwide.
*Request Sample Pages of this Report*
*Key Market Takeaways:*
· Among product type, anti-static bag segment held a significant market share in the global ESD bags market in 2017, owing to increasing demand for its applications in electronics industry. Major application of anti-static bag is packaging of electronic products. Computer components and items of a similar nature can be easily damaged by static discharge. Anti-static bags are used to maintain a static-free environment for electronic products.
· Asia Pacific accounted for a significant market share in 2017 in the global ESD bags market over the forecast period. This is owing to increasing demand for ESD bags such as anti-static bags from pharmaceutical industry in the region. ESD bags ensure that there is no electrostatic charge present inside the bag used for packaging of bulk drugs manufactured by the pharmaceutical industries. Furthermore, these bags are lightweight and have high load bearing capacity. According to India Brand Equity Foundation (IBEF), the pharmaceutical sector in India accounted for 2.4% of the global pharmaceutical industry in terms of value in 2017 and is expected to expand at a CAGR of 12.89% during 2015 to 2020
· Key players operating in the global ESD bags market include, 3M Company, Miller Packaging, Protective Packaging Corporation, Digi-Key Electronics, Daklapack Group, Dou Yee Enterprises (S) Pte Ltd., Advantek, Inc., Teknis Limited, Edco Supply Corporation, Naps Polybag Co, Katzke Paper Co, Statclean Technology (S) Pte Ltd, Elcom Ltd. and Electrotek Static Controls Pvt., Ltd.
CONTACT: Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com Reported by GlobeNewswire 3 hours ago.
↧
PIX: How young Aussies surprised formidable India
Adam Zampa picked up two wickets in a miserly spell of leg spin bowling as Australia edged India by four runs in an enthralling rain-shortened Twenty20 International in Brisbane on Wednesday.
Reported by Rediff.com 3 hours ago.
↧
↧
England's Manu Tuilagi bids to prove his fitness for Australia Test
The 27-year-old centre has not yet played for his country this autumn and Eddie Jones is giving him every possible chance to make the team. The Leicester man trained on Wednesday afternoon.
Reported by MailOnline 3 hours ago.
↧
OPTIZMO™ Sponsoring MailCon Las Vegas 2019
The company is the Official Compliance Sponsor for the email marketing event
AUSTIN, Texas, Nov. 21, 2018 (GLOBE NEWSWIRE) -- OPTIZMO Technologies, the industry leader in email suppression list management, has announced that it will be sponsoring MailCon on January 5, 2019, marking the second time the company has sponsored or exhibited at the event. The company will be the event’s first ever Official Compliance Sponsor. The company is excited for the opportunity to meet face-to-face with email marketers from around the world to learn more about their needs and identify ways to help make them more successful. Many MailCon attendees access OPTIZMO’s suppression list management platform on a regular basis, to download suppression files, cleanse mailing lists, and obtain approved campaign creative and opt-out links.
“In a short time, MailCon has developed into a great event for the email marketing industry, and we’re looking forward to participating in the show again in 2019,” said Khris Thayer, CEO of OPTIZMO. “OPTIZMO is excited to be the Official Compliance Sponsor for the event and we’re looking forward to meeting with mailers from around the world to discuss how we can help enhance their processes and simplify their workflows, while always supporting their compliance efforts.”
Since its inception in 2017, MailCon has drawn an international crowd of email marketers from around the world. Attendees come to network with other successful mailers and attend sessions on key industry topics around brand safety and compliance, deliverability, automation tools, and performance analytics, among others. Presenters are experienced email marketing pros, with extensive backgrounds in the industry.
OPTIZMO will exhibit at booth #123 during the event which takes place on Saturday, January 5, 2019 at Caesar’s Palace in Las Vegas. Several OPTIZMO team members will be in attendance, to meet with clients and partners, attend educational sessions, and network with 500+ MailCon attendees.
Following MailCon, the OPTIZMO team will be staying in Las Vegas to attend Affiliate Summit West from January 6-8, 2019.
*About OPTIZMO*
OPTIZMO Technologies is the recognized thought-leader in the email and online marketing space for email suppression list management, email campaign management, data management, and risk mitigation services relative to email compliance. With an expert staff in pursuit of unrivaled efficiency, innovative technology and an insatiable desire to problem-solve, clients find a customer-centric business model that not only enhances the way OPTIZMO clients do business, but drives the company forward. The company is headquartered in Austin, TX, and has offices and team members in Charleston, Denver, and Brisbane, Australia.
Media Contact:
Tom Wozniak
tom@optizmo.com Reported by GlobeNewswire 3 hours ago.
AUSTIN, Texas, Nov. 21, 2018 (GLOBE NEWSWIRE) -- OPTIZMO Technologies, the industry leader in email suppression list management, has announced that it will be sponsoring MailCon on January 5, 2019, marking the second time the company has sponsored or exhibited at the event. The company will be the event’s first ever Official Compliance Sponsor. The company is excited for the opportunity to meet face-to-face with email marketers from around the world to learn more about their needs and identify ways to help make them more successful. Many MailCon attendees access OPTIZMO’s suppression list management platform on a regular basis, to download suppression files, cleanse mailing lists, and obtain approved campaign creative and opt-out links.
“In a short time, MailCon has developed into a great event for the email marketing industry, and we’re looking forward to participating in the show again in 2019,” said Khris Thayer, CEO of OPTIZMO. “OPTIZMO is excited to be the Official Compliance Sponsor for the event and we’re looking forward to meeting with mailers from around the world to discuss how we can help enhance their processes and simplify their workflows, while always supporting their compliance efforts.”
Since its inception in 2017, MailCon has drawn an international crowd of email marketers from around the world. Attendees come to network with other successful mailers and attend sessions on key industry topics around brand safety and compliance, deliverability, automation tools, and performance analytics, among others. Presenters are experienced email marketing pros, with extensive backgrounds in the industry.
OPTIZMO will exhibit at booth #123 during the event which takes place on Saturday, January 5, 2019 at Caesar’s Palace in Las Vegas. Several OPTIZMO team members will be in attendance, to meet with clients and partners, attend educational sessions, and network with 500+ MailCon attendees.
Following MailCon, the OPTIZMO team will be staying in Las Vegas to attend Affiliate Summit West from January 6-8, 2019.
*About OPTIZMO*
OPTIZMO Technologies is the recognized thought-leader in the email and online marketing space for email suppression list management, email campaign management, data management, and risk mitigation services relative to email compliance. With an expert staff in pursuit of unrivaled efficiency, innovative technology and an insatiable desire to problem-solve, clients find a customer-centric business model that not only enhances the way OPTIZMO clients do business, but drives the company forward. The company is headquartered in Austin, TX, and has offices and team members in Charleston, Denver, and Brisbane, Australia.
Media Contact:
Tom Wozniak
tom@optizmo.com Reported by GlobeNewswire 3 hours ago.
↧
Watch: Gautam Gambhir trolls his 'stylist' Ashish Nehra after commentary debut during India vs Australia, 1st T20I
Gautam Gambhir, who last played a One-Day International (ODI) in 2013 and last played a Twenty20 International (T20I) in 2012, made his commentary debut during the first T20I between India and Australia on Wednesday.
Reported by DNA 2 hours ago.
↧
More Pages to Explore .....
